HC Wainwright Lowers Nuvation Bio (NYSE:NUVB) Price Target to $10.00

Nuvation Bio (NYSE:NUVB) had its price target trimmed by HC Wainwright from $11.00 to $10.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Nuvation Bio’s Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.71) EPS.

NUVB has been the subject of several other research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price objective (up previously from $6.00) on shares of Nuvation Bio in a research note on Tuesday, January 7th. Wedbush reissued an “outperform” rating and issued a $5.00 price objective on shares of Nuvation Bio in a research note on Monday, March 3rd. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $8.33.

Nuvation Bio Trading Down 2.0 %

Shares of Nuvation Bio stock opened at $2.25 on Monday. The company has a 50 day moving average of $2.38 and a 200-day moving average of $2.57. Nuvation Bio has a 1-year low of $1.67 and a 1-year high of $4.16. The company has a market cap of $755.59 million, a PE ratio of -1.03 and a beta of 1.47.

Hedge Funds Weigh In On Nuvation Bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. State Street Corp increased its position in Nuvation Bio by 4.8% in the 3rd quarter. State Street Corp now owns 4,166,441 shares of the company’s stock valued at $9,541,000 after acquiring an additional 191,031 shares during the period. Wellington Management Group LLP increased its position in Nuvation Bio by 83.3% in the 3rd quarter. Wellington Management Group LLP now owns 623,973 shares of the company’s stock valued at $1,429,000 after acquiring an additional 283,642 shares during the period. Geode Capital Management LLC increased its position in Nuvation Bio by 5.1% in the 3rd quarter. Geode Capital Management LLC now owns 4,028,692 shares of the company’s stock valued at $9,227,000 after acquiring an additional 196,247 shares during the period. JPMorgan Chase & Co. increased its position in Nuvation Bio by 479.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 442,913 shares of the company’s stock valued at $1,014,000 after acquiring an additional 366,429 shares during the period. Finally, Point72 Asset Management L.P. acquired a new position in Nuvation Bio in the 3rd quarter valued at approximately $634,000. 61.67% of the stock is currently owned by institutional investors and hedge funds.

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.